Ibrutinib and Bruton’s Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Focus on Atrial Fibrillation and Ventricular Tachyarrhythmias/Sudden Cardiac Death

Chemotherapy · Published 2022-11-10 · DOI 10.1159/000528019

Authors being retrieved — see the publisher record. https://doi.org/10.1159/000528019

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2022

Related articles

• Bruton tyrosine kinase inhibitors and cardiovascular adverse events · British Journal of Pharmacology · 2026 · Cites or is cited by this article
• Daptomycin-Induced Eosinophilic Pneumonia: A Case Report and Systematic Review · Chemotherapy · 2023 · Same journal
• Natural Compounds with Antimicrobial Activities in Oral Candida Infections during Head and Neck Radiotherapy · Chemotherapy · 2023 · Same journal
• Changing and Evolution of Influenza Virus: Is It a Trivial Flu? · Chemotherapy · 2024 · Same journal
• Gaza’s First Polio Case in 25 Years: Is Health Infrastructure Collapse Threatening Resilience? · Chemotherapy · 2024 · Same journal
• Fighting Antimicrobial Resistance and Healthcare-Associated Infections in EU-JAMRAI: The One-Health Response from Italy · Chemotherapy · 2023 · Same journal
• Therapeutic Drug Monitoring: A Driver to Precision Medicine for Patients with Hematological Malignancies · Chemotherapy · 2025 · Same journal
• Meningococcal Conjunctivitis in a 54-Year-Old Man: Case Report and Review of the Literature · Chemotherapy · 2023 · Same journal
• Circulating Endothelial Cell Kinetic in Patients with Multiple Myeloma Who Receive Autologous Hematopoietic Stem Cell Transplantation · Chemotherapy · 2023 · Same journal
• Fluorodeoxyglucose-Positron Emission Tomography in Relapsed/Refractory Hodgkin Lymphoma: A Practical Approach · Chemotherapy · 2023 · Same journal